Nusinersen Expanded Access Programme - What You Can Do To Help
17 March 2017
While we wait for the European Medicines Agency (EMA) to complete its review of the application from Biogen for a licence for nusinersen in Europe, our focus, along with the SMA Trust, is on trying to get NHS England to agree a potential commissioning framework to support the provision of this new and first treatment for SMA. In the short term this would be so that eligible children with SMA Type 1 can access the drug via the Expanded Access Programme (EAP). At the same time this would establish a longer term potential framework for access to the treatment by others affected by SMA.